St. Jude Medical Announces First Use of Renal Denervation Technology
October 17 2011 - 5:15PM
Business Wire
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the first use of the company’s renal
denervation catheter and generator system, as part of a feasibility
study of the new technology. The technology was developed as a
treatment for resistant hypertension (high blood pressure that is
not well controlled by drug therapy). Prof. Stephen Worthley,
Helpman Chair of Cardiovascular Medicine at the University of
Adelaide, performed the first procedure at the Royal Adelaide
Hospital in South Australia.
“We have leveraged our company’s extensive experience in
ablation technologies to develop a renal denervation system that
provides physicians with an alternative therapeutic option for
patients with resistant hypertension,” said Frank Callaghan,
president of the St. Jude Medical Cardiovascular Division. “This
technology could potentially help alleviate some of the $500
billion impact that hypertension has on our health care systems by
reducing or eliminating costly and lifelong medication use.
Patients could potentially benefit through an overall reduction in
risks for cardiovascular side effects of hypertension, including
death.”
Commenting on the procedure, Prof. Worthley said, “The design of
this catheter minimizes the need for extensive catheter
manipulation, which could potentially shorten procedure time, limit
contrast use and reduce fluoroscopic exposure for me, my patients
and other cath lab staff.”
Hypertension is defined as systolic blood pressure over 140 mmHg
or diastolic blood pressure over 90 mmHg. For every 20 mmHg rise in
systolic blood pressure, the risk for cardiovascular disease
doubles. Approximately 75 million patients in the U.S. have
hypertension, with more than five million patients resistant to
drug therapy.
St. Jude Medical expects a limited market launch in Europe
before the end of 2012.
About St. Jude MedicalSt. Jude Medical develops medical
technology and services that focus on putting more control into the
hands of those who treat cardiac, neurological and chronic pain
patients worldwide. The company is dedicated to advancing the
practice of medicine by reducing risk wherever possible and
contributing to successful outcomes for every patient. St. Jude
Medical is headquartered in St. Paul, Minn. and has four major
focus areas that include: cardiac rhythm management, atrial
fibrillation, cardiovascular and neuromodulation. For more
information, please visit sjm.com.
Forward-Looking StatementsThis news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including
potential clinical successes, anticipated regulatory approvals and
future product launches, and projected revenues, margins, earnings
and market shares. The statements made by the Company are based
upon management’s current expectations and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include market conditions and other
factors beyond the Company’s control and the risk factors and other
cautionary statements described in the Company’s filings with the
SEC, including those described in the Risk Factors and Cautionary
Statements sections of the Company’s Annual Report on Form 10-K for
the fiscal year ended January 1, 2011 and Quarterly Report on Form
10-Q for the fiscal quarter ended July 2, 2011. The Company does
not intend to update these statements and undertakes no duty to any
person to provide any such update under any circumstance.
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024